Aclarion, Inc. (ACON)
$
3.06
-0.22 (-7.19%)
Key metrics
Financial statements
Free cash flow per share
-13.5 Million
Market cap
1.8 Million
Price to sales ratio
23.5066
Debt to equity
0
Current ratio
14.8058
Income quality
0.9904
Average inventory
0
ROE
-0.0000
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aclarion, Inc., a healthcare technology company, specializes in developing software applications for magnetic resonance spectroscopy (MRS) across the United States. The company offers the NOCISCAN-LS Post-Processor suite, which includes NOCICALC-LS, designed to receive and process acquired disc MRS data to calculate levels of degenerative pain biomarkers, as well as NOCIGRAM-LS, a clinical decision support software. Founded in 2008 and based in San Mateo, California, Aclarion, which was previously known as Nocimed, Inc. before rebranding in December 2021, has its earnings per share (EPS) reported at -$13.61 indicating the company's profitability on a per-share basis. The total costs and expenses for the company amount to $7,128,121.00 reflecting its overall spending. Furthermore, the cost of revenue is $296,308.00 showcasing its production and operational expenses. The EBITDA is -$6,824,985.00 a key indicator of the company's operational profitability; however, the company reported a net loss of -$7,233,629.00 indicating challenges within its operations. The stock is affordable at $9.40 making it suitable for budget-conscious investors. With an average trading volume of 891,984.00 the stock indicates moderate liquidity in the market. Aclarion, Inc. has a market capitalization of $1,780,155.00 categorizing it as a small-cap player in the financial arena. As a significant participant in the Medical - Healthcare Information Services industry, the company contributes immensely to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is Aclarion, Inc. (ACON) a good investment?
Investing in Aclarion, Inc. (ACON) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Aclarion, Inc. (ACON)'s stock forecast?
Analysts predict Aclarion, Inc. stock to fluctuate between $2.34 (low) and $21.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aclarion, Inc.'s market capitalization?
As of 2026-03-27, Aclarion, Inc.'s market cap is $1,780,155, based on 581,750 outstanding shares.
How does Aclarion, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aclarion, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aclarion, Inc. (ACON) stock?
To buy Aclarion, Inc. (ACON) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACON. Place an order (Market, Limit, etc.).
What is the best time to invest in Aclarion, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Aclarion, Inc. stock ever split?
Aclarion, Inc.'s last stock split was 1:27 on 2025-03-28.
How did Aclarion, Inc. perform in the last earnings report?
Revenue: $75,730 | EPS: -$13.61 | Growth: -99.82%.
Where can I find Aclarion, Inc.'s investor relations reports?
Visit https://www.aclarion.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aclarion, Inc.?
You can explore historical data from here
What is the all-time high and low for Aclarion, Inc. stock?
All-time high: $21,708 (2022-04-27) | All-time low: $0.61 (2025-03-14).
What are the key trends affecting Aclarion, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prismmediawire.com
BROOMFIELD, Colo., March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”).
globenewswire.com
BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”).
prismmediawire.com
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 Broomfield, CO, March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
globenewswire.com
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's recent momentum and value-creating priorities for 2026.
prismmediawire.com
Broomfield, CO, March 17, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution)– Aclarion, Inc.
globenewswire.com
BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate in the 38th Annual ROTH Conference, March 22-24, 2026, in Dana Point, CA.
globenewswire.com
BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders.
prismmediawire.com
Broomfield, CO, February 5, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
globenewswire.com
Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman.
prismmediawire.com
Broomfield, CO, February 03, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with Source Healthcare, a state-of-the-art orthopedic and regenerative health clinic in Los Angeles to help address a key gap in addressing low back pain.
See all news
